Ask AI

Capsule Summary Slidesets

Share

Program Content

Activities

  • <i>CYP2B6</i> and Weight on EFV
    ADVANCE Post Hoc Analysis: CYP2B6 Genotype Associated With Differential Weight Gain in ART-Naive Patients Initiating Efavirenz-Based ART in South Africa
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • ATLAS-2M: Wk 48 Results
    ATLAS-2M: Switch to Long-Acting Injectable Cabotegravir + Rilpivirine Every 2 Mos Is Noninferior to Switch to Monthly Injections in Virologically Suppressed Patients at Wk 48
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 10, 2020

  • IMPAACT 2010
    IMPAACT 2010: Viral Suppression Rates at Delivery Significantly Higher With DTG Plus FTC/TAF or FTC/TDF vs EFV/FTC/TDF Initiation During Pregnancy in ART-Naive Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • Rapid ART in Youth
    Rapid and Sustained Viral Suppression Following Initiation of ART Within 72 Hrs of Diagnosis in Young Persons With HIV in New Orleans
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • BIC/FTC/TAF in Aging PWH
    BIC/FTC/TAF Efficacy and Safety Similar to DTG-Based 3-Drug Regimens at Wk 144 in ART-Naive Patients Aged 50 Yrs or Older
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • ADVANCE: Diabetes and CVD
    ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • ISL + DOR Metabolic Study
    DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • DISCOVER 96-Wks
    DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 15, 2020

  • FLAIR: Week 96 Results
    FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 11, 2020

  • GEMINI-1 & -2: Wk 96 CVW
    GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

Provided by

ProCE Banner

Supporters

Gilead

Merck & Co., Inc.

ViiV Healthcare